                               SEQUENCE LISTING

<110> MEDIMMUNE LIMITED
 
<120> COMPOUNDS AND CONJUGATES THEREOF

<130> TOP-101-WO-PCT

<140> PCT/EP2021/051263
<141> 2021-01-21

<150> 63/085,414
<151> 2020-09-30

<150> 62/964,180
<151> 2020-01-22

<160> 4     

<170> PatentIn version 3.5

<210> 1
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 1
Asn Ala Val Pro Asn Leu Arg Gly Asp Leu Gln Val Leu Ala Gln Lys 
1               5                   10                  15      


Val Ala Arg Thr Cys 
            20      


<210> 2
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> MOD_RES
<222> (4)..(18)
<223> Any amino acid

<400> 2
Asn Ala Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   10                  15      


Xaa Xaa Arg Thr Cys 
            20      


<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
Gly Gly Phe Gly 
1               


<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 4
Gly Phe Gly Gly 
1               


